LAURA Study Part 2: Radiation Oncology Perspective Podcast

Podcast | English | 2025 | 47 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

This episode of Lung Cancer Considered covers the recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC, based on the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Host Dr. Narjust Florez goes in depth with podcast guest Dr. Pamela Samson about the LAURA Trial and its implications for patients and clinicians.

Podcast Host:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Pamela Samson, MD, Assistant Professor in the Department of Radiation Oncology, Washington University, St. Louis, MO, USA